Galapagos doses first CF patient with G551D mutation in SAPHIRA 1 study

Galapagos NV (NASDAQ: GLPG) announced today the first dosing in CF patients with the G551D mutation in the SAPHIRA 1 study.
According to the news:

GLPG1837 is a candidate CFTR potentiator drug in clinical development for the treatment of Class III mutations in cystic fibrosis (CF).  The full SAPHIRA Phase 2 program will explore the safety, tolerability and efficacy of GLP1837 in CF patients with a G551D (SAPHIRA 1) or S1251N (SAPHIRA 2) Class III mutation.  First dosing of the exploratory study SAPHIRA 1 took place this week in Australia.

Onno van de Stolpe, CEO of Galapagos commented:

We are very excited about this rapid recruitment for the SAPHIRA program. We look forward to seeing to what extent our promising in vitro data translates into clinical results and are determined to deliver our novel CF compounds to patients as soon as possible.  We aim to start and report a number of clinical studies with additional compounds in the CF portfolio throughout 2016.

Click here to view the full press release.